Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)

Plain-language summary

This study evaluates how urothelial cancer screening using a urine tumor DNA test performs compared with urine cytology in individuals with Lynch syndrome. Individuals aged 50-75 with a diagnosis of Lynch syndrome may take part. The study is being conducted as a non-phase screening study and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Tampere University Hospital

Intervention

Urothelial cancer screening using urine tumor DNA test, Urothelial cancer screening using urine cytology (comparator)

Start date

4/10/2023

Estimated completion

12/31/2034

Countries

Canada, Finland

Related genes

Locations

• Vancouver, Canada
• Tampere, Finland

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Willing and able to provide informed consent
* Diagnosis of Lynch syndrome
* Age 50 - 75 years at study recruitment

Exclusion Criteria:

* Concurrent urothelial carcinoma